Polymorphisms Associated with Resistance and Cross-Resistance to Aminoglycosides and Capreomycin in Mycobacterium tuberculosis Isolates from South Korean Patients with Drug-Resistant Tuberculosis
- 1 February 2010
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 48 (2), 402-411
- https://doi.org/10.1128/jcm.01476-09
Abstract
The aminoglycosides streptomycin, amikacin, and kanamycin and the cyclic polypeptide capreomycin are all widely used in second-line therapy for patients who develop multidrug-resistant tuberculosis. We have characterized a set of 106 clinical isolates of Mycobacterium tuberculosis using phenotypic drug susceptibility testing (DST) to determine the extent of resistance to each agent and cross-resistance between agents. These results were compared with polymorphisms in the DNA sequences of ribosome-associated genes previously implicated in resistance and with the clinical outcomes of subjects from whom these isolates were obtained. Thirty-six (34%) of these isolates displayed resistance to one or more of these agents, and the majority of these (20 of 36) showed cross-resistance to one or more agents. Most (33 of 36) of the resistant isolates showed polymorphisms in the 16S ribosome components RpsL and rrs. Three resistant strains (3 of 36) were identified that had no known polymorphisms in ribosomal constituents. For kanamycin and streptomycin, molecular DST significantly outperformed phenotypic DST using the absolute concentration method for predicting 4-month sputum conversion (likelihood ratios of 4.0 and 2.0, respectively) and was equivalent to phenotypic DST using the National Committee for Clinical Laboratory Standards (NCCLS)-approved agar proportion method for estimating MIC (likelihood ratio, 4.0). These results offer insight into mechanisms of resistance and cross-resistance among these agents and suggest that the development of rapid molecular tests to distinguish polymorphisms would significantly enhance clinical utility of this important class of second-line antituberculosis drugs.This publication has 31 references indexed in Scilit:
- The Global Burden of Tuberculosis — Combating Drug Resistance in Difficult TimesThe New England Journal of Medicine, 2009
- Feasibility of the GenoType MTBDR sl Assay for Fluoroquinolone, Amikacin-Capreomycin, and Ethambutol Resistance Testing of Mycobacterium tuberculosis Strains and Clinical SpecimensJournal of Clinical Microbiology, 2009
- Direct susceptibility testing for multi drug resistant tuberculosis: A meta-analysisBMC Infectious Diseases, 2009
- GenoType MTBDR plus Assay for Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Strains and Clinical SamplesJournal of Clinical Microbiology, 2008
- Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug-resistant tuberculosisCurrent Opinion in Infectious Diseases, 2008
- Identification of Mutations Related to Streptomycin Resistance in Clinical Isolates of Mycobacterium tuberculosis and Possible Involvement of Efflux MechanismAntimicrobial Agents and Chemotherapy, 2008
- Molecular Characterization of Ofloxacin-Resistant Mycobacterium tuberculosis Strains from RussiaAntimicrobial Agents and Chemotherapy, 2008
- Detection of mutations in Mycobacterium tuberculosis genome determining resistance to fluoroquinolones by hybridization on biological microchipsBulletin of Experimental Biology and Medicine, 2008
- Use of the Genotype MTBDR Assay for Rapid Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Complex IsolatesJournal of Clinical Microbiology, 2005
- Susceptibility Testing for MycobacteriaClinical Infectious Diseases, 2000